The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation

Germline variants within BRCA1 or BRCA2 genes account for approximately 25% of familial aggregations of breast-ovarian cancers. Low or no expression of BRCA1 in breast and ovarian cancers is associated with a good clinical response to treatment with platinum therapies and PARP1 inhibitors. Recent st...

Descripción completa

Detalles Bibliográficos
Autores principales: Strumidło, Agnieszka, Skiba, Sylwia, Scott, Rodney J., Lubiński, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622493/
https://www.ncbi.nlm.nih.gov/pubmed/29021870
http://dx.doi.org/10.1186/s13053-017-0076-7
_version_ 1783267920477945856
author Strumidło, Agnieszka
Skiba, Sylwia
Scott, Rodney J.
Lubiński, Jan
author_facet Strumidło, Agnieszka
Skiba, Sylwia
Scott, Rodney J.
Lubiński, Jan
author_sort Strumidło, Agnieszka
collection PubMed
description Germline variants within BRCA1 or BRCA2 genes account for approximately 25% of familial aggregations of breast-ovarian cancers. Low or no expression of BRCA1 in breast and ovarian cancers is associated with a good clinical response to treatment with platinum therapies and PARP1 inhibitors. Recent studies demonstrated that microRNAs - small non-coding RNAs, involved in the control of gene expression, can decrease BRCA1 expression by targeting the 3’UTR region of the gene. This article reviews reported relationships between various miRNAs, such as miRNA-9, miRNA-146a, miRNA-182 miRNA-218, miRNA-638 and the response to cytostatic drugs, mainly to platins and PARP1 inhbitors, for the treatment of breast and ovarian cancer associated with BRCA1 mutations.
format Online
Article
Text
id pubmed-5622493
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56224932017-10-11 The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation Strumidło, Agnieszka Skiba, Sylwia Scott, Rodney J. Lubiński, Jan Hered Cancer Clin Pract Review Germline variants within BRCA1 or BRCA2 genes account for approximately 25% of familial aggregations of breast-ovarian cancers. Low or no expression of BRCA1 in breast and ovarian cancers is associated with a good clinical response to treatment with platinum therapies and PARP1 inhibitors. Recent studies demonstrated that microRNAs - small non-coding RNAs, involved in the control of gene expression, can decrease BRCA1 expression by targeting the 3’UTR region of the gene. This article reviews reported relationships between various miRNAs, such as miRNA-9, miRNA-146a, miRNA-182 miRNA-218, miRNA-638 and the response to cytostatic drugs, mainly to platins and PARP1 inhbitors, for the treatment of breast and ovarian cancer associated with BRCA1 mutations. BioMed Central 2017-09-29 /pmc/articles/PMC5622493/ /pubmed/29021870 http://dx.doi.org/10.1186/s13053-017-0076-7 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Strumidło, Agnieszka
Skiba, Sylwia
Scott, Rodney J.
Lubiński, Jan
The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation
title The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation
title_full The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation
title_fullStr The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation
title_full_unstemmed The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation
title_short The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation
title_sort potential role of mirnas in therapy of breast and ovarian cancers associated with brca1 mutation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622493/
https://www.ncbi.nlm.nih.gov/pubmed/29021870
http://dx.doi.org/10.1186/s13053-017-0076-7
work_keys_str_mv AT strumidłoagnieszka thepotentialroleofmirnasintherapyofbreastandovariancancersassociatedwithbrca1mutation
AT skibasylwia thepotentialroleofmirnasintherapyofbreastandovariancancersassociatedwithbrca1mutation
AT scottrodneyj thepotentialroleofmirnasintherapyofbreastandovariancancersassociatedwithbrca1mutation
AT lubinskijan thepotentialroleofmirnasintherapyofbreastandovariancancersassociatedwithbrca1mutation
AT strumidłoagnieszka potentialroleofmirnasintherapyofbreastandovariancancersassociatedwithbrca1mutation
AT skibasylwia potentialroleofmirnasintherapyofbreastandovariancancersassociatedwithbrca1mutation
AT scottrodneyj potentialroleofmirnasintherapyofbreastandovariancancersassociatedwithbrca1mutation
AT lubinskijan potentialroleofmirnasintherapyofbreastandovariancancersassociatedwithbrca1mutation

Ejemplares similares